Brain Dopamine Receptors in Schizophrenia and Tardive Dyskinesia

  • P. Seeman
Part of the Psychopharmacology Supplementum book series (PSYCHOPHARM, volume 2)


Brain dopamine receptors (type D2) mediate the psychomotor effects of dopamine. The D2 dopamine receptor can exist in either a high-affinity state for dopamine (nanomolar dissociation constant) or in a low-affinity state (micromolar dissociation constant). Both states of the receptor, however, have high affinity for neuroleptics (60 pM for spiperone). The postsynaptic receptor probably operates mainly in the D 2 low state. The presynaptic dopamine receptor, and also the dopamine receptors in the pituitary gland and the area postrema, probably function in the D 2 high state. The density of brain D2 dopamine receptors is elevated in schizophrenia. The control densities were 10.5 pmol per g tissue. Half of the schizophrenic tissues (putamen, caudate nucleus, and nucleus accumbens) revealed densities of about 11.9 pmol per g, while the other half of the tissues revealed a density mode of 23.8 pmol per g. The bimodal distribution may support the concept of two types of schizophrenia. Future work must decide which group has more tardive dyskinesia.


Dopamine Receptor Adenylate Cyclase Tardive Dyskinesia Schizophrenic Brain Presynaptic Dopamine Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cote TE, Greve CW, Kebabian JW (1981) Stimulation of a D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland decreases the responsiveness of the betaadrenoceptor: biochemical mechanism. Endocrinology 108: 420–426PubMedCrossRefGoogle Scholar
  2. Cross AJ, Crow TJ, Owen F (1981) 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology 74: 122–124PubMedCrossRefGoogle Scholar
  3. Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66PubMedCrossRefGoogle Scholar
  4. Crow TJ (1982) The biology of schizophrenia. Experientia 38: 1275–1282PubMedCrossRefGoogle Scholar
  5. DeCamilliP, Macconi D, SpadaA (1979) Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 278: 252–254CrossRefGoogle Scholar
  6. DeLean A, Kilpatrick BF, Caron MG (1982) Dopamine receptor of porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. Mol Pharmacol 22: 290–297Google Scholar
  7. George SR, Watanabe M, Seeman P (1983a) Commentary: the dopamine receptor of the anterior pituitary gland. In: Kaiser C, Kebabian JW (eds) Dopamine receptors. Am Chem Soc, WashingtonGoogle Scholar
  8. George SR, Binkley K, Seeman P (1983b) Dopamine receptor sites and states in human brain. J Neural Transm [Suppl] 18: 149–156Google Scholar
  9. George SR, Watanabe M, Di Paolo T, Labrie F, Seeman P (1984) The functional state of the dopamine receptor in the anterior pituitary is in the high-affinity form. Endocrinology (to be published)Google Scholar
  10. Grigoriadis D, Seeman P (1984) Complete conversion of brain D2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide. J Neurochem (to be published)Google Scholar
  11. Hamblin MW, Creese I (1982) 3H-Dopamine binding to rat striatal D-2 and D-3 sites: enhancement by magnesium and inhibition by guanine nucleotides and sodium. Life Sci 30: 1587–1595Google Scholar
  12. Huff RM, Molinoff PB (1982) Quantitative determination of dopamine receptor subtypes not linked to activation of adenylate cyclase in rat striatum. Proc Natl Acad Sci USA 79: 7561–7565PubMedCrossRefGoogle Scholar
  13. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  14. Lee T, Seeman P (1977) Dopamine receptors in normal and schizophrenic human brains. Abstracts of the Society for Neuroscience 3: 443Google Scholar
  15. Lee T, Seeman P (1980) Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am J Psychiatry 137: 191–197PubMedGoogle Scholar
  16. Lee T, Seeman P, Tourtellote WW, Farley I J, Hornykiewicz O (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274: 897–900PubMedCrossRefGoogle Scholar
  17. Leff SE, Creese I (1983) Dopamine receptors re-explained. Trends in Pharmacological Science 4: 463–467CrossRefGoogle Scholar
  18. List S, Seeman P (1982) 3H-Dopamine labelling of D3 dopaminergic sites in human, rat and calf brain. J Neurochem 39: 1363–1373Google Scholar
  19. List S, Titeler M, Seeman P (1980) High-affinity 3H-dopamine receptors (D3 sites) in human and rat brain. Biochem Pharmacol 29: 1621–1622PubMedCrossRefGoogle Scholar
  20. MacKay AVP, Bird ED, Spokes EG, Rossor M, Iversen LL, Creese I, Snyder SH (1980) Dopamine receptors and schizophrenia: drug effect or illness? Lancet 11: 915–916CrossRefGoogle Scholar
  21. MacKay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39: 991–997PubMedGoogle Scholar
  22. Meunier H, Giguere V, Labrie F (1980) Dopamine receptors are negatively coupled to adenylate cyclase in rat intermediate pituitary cells. Proceedings of the 4th international conference on cyclic nucleotides, July 1980, Abstr. THA9Google Scholar
  23. Munson P, Rodbard D (1980) “Ligand”: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220–239PubMedCrossRefGoogle Scholar
  24. Owen F, CrowTJ, Poulter M, Cross AJ, LongdenA, Riley GJ (1978) Increased dopamine-receptor sensitivity in schizophrenia. Lancet 11: 223–226CrossRefGoogle Scholar
  25. Reynolds GP, Reynolds LM, Riederer P, Jellinger K, Gabriel E (1980) Dopamine receptors and schizophrenia: drug effect or illness. Lancet 11: 1251CrossRefGoogle Scholar
  26. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313PubMedGoogle Scholar
  27. Seeman P (1981) Dopamine receptors in post-mortem schizophrenic brains. Lancet 1: 1103PubMedCrossRefGoogle Scholar
  28. Seeman P (1982) Nomenclature of central and peripheral dopaminergic sites and receptors. Biochem Pharmacol 31: 2563–2568PubMedCrossRefGoogle Scholar
  29. Seeman P, Lee T (1977) In: Timnick L (ed) Scientists find ‘sites of craziness’. Los Angeles Times 200: 1Google Scholar
  30. Seeman P, Lee T (1982) Dopamine receptors in the schizophrenic brain. In: Namba M, Kaiya H (eds) Psychobiology of schizophrenia. Pergamon, Oxford, pp 241–247Google Scholar
  31. Seeman P, Ulpian C, Wells J (1982) Dopamine receptor parameters (detected by 3H-spiperone) depend on tissue concentration. Abstracts of the Society for Neuroscience 8: 718Google Scholar
  32. Seeman P, Ulpian C, Wreggett KA, Wells J (1984a) Dopamine receptor parameters detected by 3H-spiperone depend on tissue concentration: analysis and examples. J Neurochem (to be published)Google Scholar
  33. Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtellotte WW (1984b) Bimodal distribution of schizophrenic brain dopamine receptor densities (to be published )Google Scholar
  34. Seeman P, Grigoriadis D, George SR, Watanabe M (1984c) Functional states of dopamine receptors. In: Woodruff GN, Creese I, Gessa GL, Hornykiewicz O, Poat JA, Roberts PJ (eds) Dopaminergic systems and their regulation. Macmillan, London (to be published)Google Scholar
  35. Sibley DR, Creese I (1983) Regulation of ligand binding to pituitary D-2 dopaminergic receptors. Effects of divalent cations and functional group modification. J Biol Chem 258: 4957–4965PubMedGoogle Scholar
  36. Sibley DR, DeLean A, Creese I (1982) Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D2 dopamine receptor. J Biol Chem 257: 6351–6361PubMedGoogle Scholar
  37. Stoof JC, Kebabian JW (1981) Opposing roles for D-l and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366–368PubMedCrossRefGoogle Scholar
  38. Stoof JC, Kebabian JW (1982) Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K-stimulated release of acetylcholine from rat neostriatum. Brain Res 250: 263–270PubMedCrossRefGoogle Scholar
  39. Watanabe M, George SR, Seeman P (1983) The proportion of D2 dopamine receptors in high and low affinity states depends on the agonist, cations, guanine nucleotides and temperature. Abstracts of the Society for Neuroscience 9: 994Google Scholar
  40. Wreggett KA, Seeman P (1984) Agonist high- and low-affinity states of the D2 dopamine receptor in calf brain: partial conversion by guanine nucleotide. Mol Pharmacol (to be published)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • P. Seeman
    • 1
  1. 1.Department of PharmacologyUniversity of TorontoTorontoCanada

Personalised recommendations